This article was originally published in The Gray Sheet
Purchase of the global intra-aortic balloon catheter and pump business of C.R. Bard is completed ("The Gray Sheet" Aug. 18, p. 7). The Reading, Pennsylvania-based firm expects the transaction to be accretive to fiscal year 1999 earnings. However, a pretax charge to income of about $7 mil. is expected in the second quarter (ending Feb. 28) related to in-process R&D. The after tax charge will be approximately $4.5 mil. or 19 cents per share, the firm says
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.